# Mouse EPHB2 Protein

**Cat. No.** EPH-MM101

## Description

| | |
|---|---|
| **Source** | Recombinant Mouse EPHB2 Protein is expressed from HEK293 with His tag at the C-Terminus. |
| | It contains Val19-Leu543. |
| **Accession** | P54763-3 |
| **Molecular Weight** | The protein has a predicted MW of 59.3 kDa. Due to glycosylation, the protein migrates to 60-70 kDa based on Tris-Bis PAGE result. |
| **Endotoxin** | Less than 1EU per μg by the LAL method. |
| **Purity** | > 95% as determined by Tris-Bis PAGE |
| | > 95% as determined by HPLC |

## Formulation and Storage

| | |
|---|---|
| **Formulation** | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| **Reconstitution** | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| **Storage** | -20 to -80°C for 12 months as supplied from date of receipt.-20 to -80°C for 3-6 months in unopened state after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |

## Background

EphB2, a receptor tyrosine kinase for ephrin ligands, is overexpressed in various cancers and plays an important role in tumor progression. EPHB2 promotes endothelial-mesenchymal transition (EMT) and elicits associated pathologic characteristics of glioblastoma multiforme (GBM) such as invasion and migration. EPHB2 is epigenetically overexpressed in hypoxia, a condition highly prevalent in malignancy. Furthermore, HIF-2α is required for EPHB2 stabilization by hypoxia.

## Assay Data

### Tris-Bis PAGE




Human EPHB2 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

### SEC-HPLC

# Mouse EPHB2 Protein

**Cat. No.** EPH-MM101

## Assay Data




The purity of Human EPHB2 is greater than 95% as determined by SEC-HPLC.